Table 1.
Characteristics of 188 980 cases of RT-PCR-confirmed SARS-CoV-2 between Nov 21 and Dec 19, 2021, in Denmark
|
SARS-CoV-2 infection |
COVID-19 hospitalisation |
|||
|---|---|---|---|---|
| Omicron (N=38 669) | Delta (N=150 311) | Omicron (N=222) | Delta (N=2213) | |
| COVID-19 vaccination (status at infection)* | ||||
| None or only one dose | 7266 (18·8%) | 69 885 (46·5%) | 54 (24·3%) | 997 (45·1%) |
| Two doses | 29 922 (77·4%) | 77 441 (51·5%) | 145 (65·3%) | 1041 (47·0%) |
| Three doses | 1481 (3·8%) | 2985 (2·0%) | 23 (10·4%) | 175 (7·9%) |
| Sex | ||||
| Female | 19 432 (50·3%) | 75 723 (50·4%) | 135 (60·8%) | 1117 (50·5%) |
| Male | 19 237 (49·7%) | 74 588 (49·6%) | 87 (39·2%) | 1096 (49·5%) |
| Age, years | ||||
| Median, IQR | 29·0 (20·0–45·0) | 31·0 (11·0–48·0) | 38·5 (27·0–59·0) | 56·0 (35·0–74·0) |
| 0–9 | 2118 (5·5%) | 26 883 (17·9%) | 11 (5·0%) | 128 (5·8%) |
| 10–19 | 6783 (17·5%) | 26 865 (17·9%) | 20 (9·0%) | 71 (3·2%) |
| 20–29 | 11 187 (28·9%) | 18 689 (12·4%) | 42 (18·9%) | 177 (8·0%) |
| 30–39 | 5772 (14·9%) | 20 152 (13·4%) | 41 (18·5%) | 288 (13·0%) |
| 40–49 | 5515 (14·3%) | 23 650 (15·7%) | 31 (14·0%) | 258 (11·7%) |
| 50–59 | 4704 (12·2%) | 17 136 (11·4%) | 23 (10·4%) | 279 (12·6%) |
| 60–69 | 1845 (4·8%) | 9938 (6·6%) | 21 (9·5%) | 288 (13·0%) |
| 70–79 | 557 (1·4%) | 5451 (3·6%) | 19 (8·6%) | 396 (17·9%) |
| 80–89 | 156 (0·4%) | 1326 (0·9%) | 11 (5·0%) | 280 (12·7%) |
| ≥90 | 32 (0·1%) | 221 (0·1%) | 3 (1·4%) | 48 (2·2%) |
| Number of comorbidities | ||||
| 0 | 33 782 (87·4%) | 126 164 (83·9%) | 137 (61·7%) | 1082 (48·9%) |
| ≥1 | 4887 (12·6%) | 24 147 (16·1%) | 85 (38·3%) | 1131 (51·1%) |
| Reinfection with SARS-CoV-2 | ||||
| No | 36 527 (94·5%) | 148 425 (98·7%) | 211 (95·0%) | 2177 (98·4%) |
| Yes | 2142 (5·5%) | 1886 (1·3%) | 11 (5·0%) | 36 (1·6%) |
| Test track | ||||
| Community | 35 904 (92·8%) | 137 199 (91·3%) | 119 (53·6%) | 1133 (51·2%) |
| Health care | 2765 (7·2%) | 13 112 (8·7%) | 103 (46·4%) | 1080 (48·8%) |
Data are n (%), unless otherwise specified.
*
None or only one dose: tested positive and not vaccinated, or tested positive up to 14 days after first vaccination, more than 14 days after first vaccination, or up to 14 days after second vaccination (if any); two doses: tested positive more than 14 days after second vaccination and up to 14 days after third vaccination (if any); three doses: tested positive more than 14 days after third vaccination (if any).